Nothing said here yet.
to join the conversation.
| Mainolfi NelloChief Executive Officer | Sell | 8,230 | $949.7K | Thu, Oct 1 |
| Mainolfi NelloChief Executive Officer | Sell | 7,601 | $869.8K | Thu, Oct 1 |
| Mainolfi NelloChief Executive Officer | Sell | 5,506 | $619.0K | Thu, Oct 1 |
| Mainolfi NelloChief Executive Officer | Sell | 4,876 | $552.2K | Thu, Oct 1 |
| Mainolfi NelloChief Executive Officer | Sell | 3,525 | $392.8K | Thu, Oct 1 |
| Mainolfi NelloChief Executive Officer | Sell | 262 | $30.4K | Thu, Oct 1 |
| Adams BrianChief Legal Officer | Sell | 3,025 | $353.4K | Fri, Sep 4 |
| Adams BrianChief Legal Officer | Sell | 2,137 | $251.2K | Fri, Sep 4 |
| Adams BrianChief Legal Officer | Sell | 1,209 | $139.7K | Fri, Sep 4 |
KT-579 IRF5 degrader hit 94% degradation in Phase I trials.
Kymera Therapeutics (NASDAQ:KYMR) reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune diseases.
Kymera Therapeutics (KYMR) heads into its September quarter report with investors focused on two things: sharp year over year revenue growth expectations and fresh progress around its lead immunology candidate KT-621.
For questions about this article or underlying research, email [email protected].
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.